Could adding a second diabetes drug early save lives?
NCT ID NCT07566299
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study analyzed health records of over 118,000 adults with obesity, type 2 diabetes, and related heart, kidney, and liver conditions. Researchers compared people who added a second type of diabetes drug (GLP-1 or SGLT2) early to those who did not. The goal was to see if early combination therapy reduces death risk over five years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 receptor agonist and SGLT2 inhibitor
What this could lead to
If successful, this could show that adding a second diabetes drug early improves survival and reduces heart, kidney, and liver problems in people with obesity and type 2 diabetes.
What could go wrong
This is an observational study using existing health records, not a controlled trial. Results may be affected by unmeasured factors, and the findings need confirmation in prospective studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chung Shan Medical University Hospital
Taichung, Taichung, 402, Taiwan